Literature DB >> 11864153

Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa.

Kenji Nagino1, Hiroyuki Kobayashi.   

Abstract

OBJECTIVE: The long-term administration of erythromycin (EM), clarithromycin (CAM) or azithromycin (AZM) has generally resulted in a favorable outcome for patients with diffuse panbronchiolitis (DPB) infected with mucoid Pseudomonas aeruginosa. To elucidate the mechanism involved, the influence of macrolides on mucoid alginate production by P. aeruginosa was investigated in vitro.
METHODS: The macrolides used in this study were EM with a 14-membered ring, AZM with a 15-membered ring, midecamycin (MDM) with a 16-membered ring, and CP-4305, which has had mycarose removed from MDM, The effects of macrolides on mucoid P. aeruginosa were investigated by quantitative assay of alginate production and inhibition of guanosine diphospho-D-mannose dehydrogenase activity.
RESULTS: After incubation with EM, AZM and CP-4305, the structural material of P. aeruginosa biofilm was distorted, and the enzymatic activity of GDP-D-mannose dehydrogenase, the most important enzyme in mucoid alginate biosynthesis, was inhibited. However, these effects were not observed with the 16-membered macrolide MDM.
CONCLUSIONS: The basic mechanism of clinical efficacy seen characteristically in 14- or 15-membered macrolides for patients with airway biofilm disease depends on the ability of such macrolides to inhibit alginate production by P. aeruginosa. Furthermore, this suggests that the inhibitory effect observed with 14-, 15- and 16-membered macrolides may depend on the sugar chain connected with the macrolide ring.

Entities:  

Year:  1997        PMID: 11864153     DOI: 10.1111/j.1469-0691.1997.tb00279.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.

Authors:  Yusuf Nalca; Lothar Jänsch; Florian Bredenbruch; Robert Geffers; Jan Buer; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Antibiofilm effects of azithromycin and erythromycin on Porphyromonas gingivalis.

Authors:  H Maezono; Y Noiri; Y Asahi; M Yamaguchi; R Yamamoto; N Izutani; H Azakami; S Ebisu
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

3.  Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.

Authors:  Pin-Chuang Lai; Weiting Ho; Nidhi Jain; John D Walters
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

4.  Effect of gingivitis on azithromycin concentrations in gingival crevicular fluid.

Authors:  Nidhi Jain; Pin-Chuang Lai; John D Walters
Journal:  J Periodontol       Date:  2012-02-14       Impact factor: 6.993

Review 5.  Recent Advances in Antimicrobial Nano-Drug Delivery Systems.

Authors:  Tong-Xin Zong; Ariane Pandolfo Silveira; José Athayde Vasconcelos Morais; Marina Carvalho Sampaio; Luis Alexandre Muehlmann; Juan Zhang; Cheng-Shi Jiang; Shan-Kui Liu
Journal:  Nanomaterials (Basel)       Date:  2022-05-29       Impact factor: 5.719

6.  Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms.

Authors:  Fang Li; Jialin Yu; Hua Yang; Zhenyan Wan; Dan Bai
Journal:  Curr Microbiol       Date:  2008-04-04       Impact factor: 2.188

Review 7.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

Review 8.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

9.  Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.

Authors:  Nadine Hoffmann; Baoleri Lee; Morten Hentzer; Thomas Bovbjerg Rasmussen; Zhijun Song; Helle Krogh Johansen; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 10.  State of progress in treating cystic fibrosis respiratory disease.

Authors:  Patrick A Flume; Donald R Van Devanter
Journal:  BMC Med       Date:  2012-08-10       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.